ReviewCureus2025
Adipose-Derived Stem Cell, Stromal Vascular Fraction, and Regenerative Cell Enrichment in Fat Grafting: A Systematic Review of Safety and Functional Outcomes.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Superior penile girth retention with stromal vascular fraction-enriched autologous fat grafting: a retrospective 1-year comparative study.Translational andrology and urology · 2026Article
- Combined Stromal Vascular Fraction and HGF-Functionalized Self-Assembling Peptide Hydrogel Improves Intracerebral Hemorrhage Repair in Rats.Gels (Basel, Switzerland) · 2026Article
- Advancing fat graft survival: from adipose-derived stem cell mechanisms to next-generation regenerative strategies.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adipose-derived stem cell (ADSC)-enhanced fat grafting, including enrichment with stromal vascular fraction (SVF) and adipose-derived regenerative cells (ADRCs), has been increasingly used to improve fat graft survival and regenerative outcomes in reconstructive and aesthetic plastic surgery, yet long-term safety, efficacy, and mechanistic understanding remain variably reported. This systematic review aimed to evaluate real-world clinical evidence on the long-term safety, volume retention, and functional outcomes of ADSC-, SVF-, and ADRC-enriched fat grafting across aesthetic and reconstructive indications. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, comprehensive searches of PubMed, Scopus, Web of Science, and the Cochrane Library identified 3158 studies, of which 12 met the inclusion criteria, encompassing randomized controlled trials and prospective non-randomized clinical studies assessing ADSC-, SVF-, or ADRC-assisted fat grafting with reported outcomes related to graft survival, clinical function, aesthetic performance, or safety. Across studies, ADSC and SVF enrichment generally improved volume retention compared with conventional fat grafting, with several randomized trials demonstrating graft survival rates of 60-80% at three to six months, and ADSC-assisted grafts consistently enhanced dermal regeneration by improving collagen organization, skin texture, and elastic fiber architecture. In reconstructive applications, SVF therapy reduced digital ulcers and pain in patients with systemic sclerosis, while ADRC-assisted grafting alleviated symptoms of breast cancer-related lymphedema despite limited objective limb-volume reduction, and patient satisfaction was high across all enrichment techniques. Safety outcomes were favorable, with no increase in infection, cyst formation, fat necrosis, or oncologic recurrence across follow-up periods of up to four years. Overall, ADSC-, SVF-, and ADRC-enriched fat grafting appear to offer meaningful improvements in graft survival, skin quality, and functional recovery with a strong safety profile across diverse clinical indications, although methodological heterogeneity and limited long-term data support the need for standardized, regulated, and mechanistically informed clinical protocols, as well as larger, long-term randomized trials to optimize techniques and guide clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.